Form 4: Aligos Therapeutics Executive Granted Stock Options

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Inc., was granted 16,000 stock options with an exercise price of $8.68 per share, vesting over four years.

Summary

• Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Inc. (ALGS), was granted 16,000 stock options.
• The stock options have an exercise price of $8.68 per share.
• The transaction date for the grant was July 16, 2025.
• The options are exercisable starting July 16, 2025, and expire on July 16, 2035.
• Vesting occurs in 48 successive and equal monthly installments measured from July 16, 2025, with 100% of the shares fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive signal as it aligns management's interests with shareholders, incentivizing long-term performance. It is a routine compensation event, so the positive impact is moderate.

Positives

• The grant of stock options to Julian A. Symons, a key executive, aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.

Negatives

• No direct negative information is presented in this Form 4 filing.

Risks

• The vesting of the stock options is contingent upon the reporting person's continued service through each vesting date, meaning the options could be forfeited if employment ceases before full vesting.

Future Outlook

The stock options are structured with a four-year vesting schedule, indicating a long-term incentive for the executive's continued service and contribution to the company's future performance and strategic objectives.

Industry Context

This filing represents a routine executive compensation event within the biotechnology or pharmaceutical industry, where stock options are a common tool used to attract, retain, and incentivize key scientific and management personnel by aligning their financial interests with the company's long-term success.

Comparison to Industry Standards

• Granting stock options to executives is a standard compensation practice across various industries, including biotechnology. The specific terms, such as the exercise price relative to the stock price and the multi-year vesting schedule, are typical for long-term incentive plans designed to align executive interests with shareholder value creation. Without specific comparable company data, a detailed assessment against industry benchmarks is not possible, but the structure appears consistent with general industry norms for executive equity grants.

Related Party Transactions

• The grant of stock options to Julian A. Symons, an Executive Vice President and Chief Scientific Officer, constitutes a related party transaction as it involves compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with shareholder value creation and long-term company performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The stock options will vest in 48 successive monthly installments starting July 16, 2025.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the reporting person's continued service.

Key Dates

Keywords

Aligos Therapeutics, ALGS, Form 4, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Vesting Schedule, Julian A. Symons